IntegraGen announced today its unaudited business figures for the year 2020.
- 2020 revenue amounted to 9.0 M € versus 8.1 M € in 2019, an increase of 10% over 12 months.
- Increased sequencing services reported for company’s Evry lab and at outsourced platforms run by the company for the SeqOIA project and at the Institut Pasteur.
- Growth in sales also experienced with company’s sequencing data interpretation software tools Mercury®, Sirius® and Galileo®
- Company generated positive operating cash flow throughout the year and obtained a French State Guaranteed Loan (PGE) of € 1.8 million. The company’s cash position improved from €2.8 million at the beginning of the year to €5.0 million at the end of December.